维普期刊资源整合服务平台（V6.5）

64篇 您的检索式：作者名="Quezada SA"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Principles and use of anti-CTLA4 antibody in human cancer immunotherapy显示文摘	Quezada SA Korman AJ	2006	Curr Opin Immunol2006，18，2：	1
2	Tumor-reactive CD4 ~ T cells develop cytotoxic activity and eradicate large established mel- anoma after transfer into \|ymphopenic hosts显示文摘	Quezada SA Simpson TR Peggs KS	2010	J Exp Med2010，207，3：	1
3	Cutting edge: contact- mediated suppression by CD4^+CD25^+ regulatory cells involves a granzyme B-dependent, perforin- independent mechanism 显示文摘	Gondek DC Lu LF Quezada SA	2005	J Immunol2005，174，4：	1
4	Distinct mechanisms of action of anti - CD154 in early versus late treatment of murine lupus nephritis 显示文摘	Quezada SA Eekert M Adeyi OA	2003	Arthritis Rheum2003，48，9：	1
5	Cutting edge : contact-mediated suppression by CD4^+ CD25^+ regulatory cells involves a granzyme B-dependent, pefforin-independent mechanism显示文摘	Gondek DC Lu LF Quezada SA	2005	J Immunol2005，174，4：	1
6	Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies 显示文摘	Peggs KS Quezada SA Chambers CA	2009	J Exp Med2009，206，8：	1
7	Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication显示文摘	Quezada SA Peggs KS Simpson TR	2011	Immunol Rev2011，241，1：	1
8	Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti- CTLA-4 antibodies显示文摘	Peggs KS Quezada SA Chambers CA	2009	J Exp Med2009，206，8：	1
9	Regulation of CD4+ T :ell activation and effector function by inducible costimulator (ICOS) 显示文摘	Simpson TR Quezada SA Allison JP	2010	Curr Opinlmmunol2010，22，32：	1
10	Shifting the equilibrium in cancer immunoediting : from tumor tolerance to eradication 显示文摘	Quezada SA Peggs KS Simpson TR	2011	lmmunol Rev2011，241，1：	1
11	Regulation of CD4 T cellactivation and effector function by inducible costimulator(ICOS)显示文摘	Simpson TR Quezada SA Al ison JP		0，，03：	1
12	Engagement ofthe ICOS pathway markedly enhances efficacy of CTLA-4blockade in cancer immunotherapy 显示文摘	Fan X Quezada SA Sepulveda MA	2014	J Exp Med2014，211，4：	1
13	Cancer immunotherapy: Costimulatoryagonists and co-inhibitory antagonists 显示文摘	Peqqs KS Quezada SA Allison JP	2009	Clin Exp Immunol2009，57，1：	1
14	Cutting edge:contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent,perforin-independent mechanism显示文摘	Gondek DC Lu LF Quezada SA		0，，4：	1
15	Shifting the equilibri-um in cancer immunoediting:from tumor tolerance to eradication显示文摘	Quezada SA Peggs KS Simpson TR	2011	Immunol Rev2011，241，1：	1
16	Cancer immunotherapy: Costimu- latory agonists and co-inhibitory antagonists 显示文摘	Peqqs KS Quezada SA Allison JP	2009	Clin Exp Immunol2009，157，1：	1
17	Principles and use of anti CTLA4 antibody in human cancer immunotherapy显示文摘	Peggs KS Quezada SA Korman A J	2006	Curr Opin Immunol2006，18，2：	1
18	CD40/CD154 interactions at the interface of tolerance and immunity显示文摘	Quezada SA Jarvinen LZ Lind EF	2004	Annu Rev Immunol2004，22，：	1
19	Distinctive maturation of in vitro versus in vivo anti-CD40 mAb-matured dendritic cells in mice 显示文摘	Frleta D Lin JT Quezada SA	2003	J Immunother2003，26，1：	1
20	Exploiting CTLA-4,PD-1 and PD-L1to reactivate the host immune response against cancer显示文摘	Quezada SA Peggs KS	2013	Br J Cancer2013，108，8：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示